BioNexus Gene Lab Corp. (NASDAQ:BGLC) finished Wednesday with an addition of $0.24 to close at $1.62, an upside of 17.39 percent. An average of 20,585,900 shares of common stock have been traded in the last five days. There was a gain of $0.9000 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 6,400,360 shares traded, while the 50-day average volume stands at 3,075,513.
BGLC stock has decreased by -53.71% in the last month. The company shares reached their 1-month lowest point of $0.6505 on 08/16/23. With the stock rallying to its 52-week high on 07/12/23, shares of the company touched a low of $0.65 and a high of $17.88 in 52 weeks. It has reached a new high 3 times so far this year and lost -85.79% or -$9.7800 in price. In spite of this, the price is down -90.94% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
BioNexus Gene Lab Corp. (BGLC) stock’s beta is 0.75. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.78, the price-to-book (PB) ratio at 3.95, and the price-to-cash flow ratio at 47.79.
Financial Health
The quick ratio of BioNexus Gene Lab Corp. for the recent quarter was 2.20, and the current ratio was 2.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the recent quarter. BioNexus Gene Lab Corp.’s EBITDA margin is -3.34%.
Earnings Surprise
The company posted a net income of -$0.26 million in the quarter, while revenues were grew 46.15%. At the end of the recent quarter, BioNexus Gene Lab Corp.’s stock balance sheet showed total debt was $45760.0.
Technical Picture
From a technical analysis perspective, let’s take a brief look at BioNexus Gene Lab Corp. (BGLC) price momentum. RSI 9-day as of the close on 23 August was 47.32%, suggesting the stock is Neutral, with historical volatility in this time frame at 347.31%.
As of today, BGLC’s price is $1.2020 +125.00% or $0.9000 from its 5-day moving average. BGLC is currently trading -46.89% lower than its 20-day SMA and -86.50% lower than its 100-day SMA. However, the stock’s current price level is -15.89% below the SMA50 and -92.20% below the SMA200.
The stochastic %K and %D were 47.41% and 31.35%, respectively, and the average true range (ATR) was 0.7272. With the 14-day stochastic at 68.79% and the average true range at 1.1078, the RSI (14) stands at 43.75%. The stock has reached 0.2928 on the 9-day MACD Oscillator while the 14-day reading was at 0.1715.
